Breast Cancer

PREVENTION/Control

  • SCUSF 0806 – Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer receiving (Neo) Adjuvant Chemotherapy with Trastuzumab (Herceptin)-            The Non-Anthracycline Cohort is closed to accural
  • ALLIANCE Z11102- Phase II Study of Impact of Breast-Conserving Surgery and Radiotherapy in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
  • ECOG E1Z11- A Cohort Study to Evaluate Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Women with Stage I-III Breast Cancer
  • SWOG S1202- Phase III Randomized Placebo-Controlled Study of Duloxetine for Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

RADIATION

  • RTOG 0631- A Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
  • NSABP B-51- A Phase III Randomized Clinical Trial Evaluating Standard or Comprehensive Radiation Therapy in Treating Patients with Early Stage Breast Cancer Previously Treated with Chemotherapy and Surgery

DCIS

  • NSABP B-43 – A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy And Radiation Therapy Alone For Women With Her-2 Positive Ductal Carcinoma In Situ Resected By Lumpectomy
  • CALGB 40903- A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ (DCIS)

HER2 Positive

  • NSABP B-52- A Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor Positive, Her-2 Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation

ER and/or PR Positive/HER2 Negative

  • SWOG S1207- A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer
  • ECOG E2112- A Phase III Randomized Clinical Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor -Positive that is locally Advanced or Metastatic Breast Cancer

ER OR PR POSITIVE/ NODE POSITIVE

  • SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Pts. w/1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer w/Oncotype Recurrence Score of 25 or less (QOL substudy closed to accrual effective 11/15/2012)

HER 2/NEU LOW

  • NSABP B-47 – A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (6 cycles of Docetaxel +Cyclophosphamide or 4 cycles of Doxorubicin + Cyclophosamide Followed by Weekly Paclitaxel) to Chemo + Trastuzumab in Women w/Node Positive or High Risk Node Negative HER2-Low Invasive Breast Cancer

METASTATIC

  • ECOG E2108 – A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
  • SWOG S1222- A Randomized Phase III Trial of Fulvestrant alone versus Fulvestrant and Everolimus versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor-Positive Stage IV Breast Cancer